Clinical TrialMay 11, 2026, 09:07 AM
MetaVia DA-1726 Obesity Drug Data Accepted for EASL Congress 2026
AI Summary
MetaVia Inc. announced that a late-breaking abstract highlighting its novel dual GLP-1/glucagon agonist, DA-1726, for the treatment of obesity, has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026. The presentation will take place on May 27, 2026, in Barcelona, Spain. DA-1726 is currently undergoing a 16-week Phase 1 Part 3 titration study, with data anticipated in the fourth quarter of this year, aiming to optimize higher dose levels and tolerability.
Key Highlights
- MetaVia's DA-1726 abstract accepted for late-breaking poster presentation at EASL Congress 2026.
- DA-1726 is a novel dual oxyntomodulin (OXM) analog targeting GLP-1 and glucagon receptors for obesity.
- The poster presentation is scheduled for Wednesday, May 27, 2026, at 8:30 am CET.
- DA-1726 is currently being evaluated in a 16-week Phase 1 Part 3 titration study.
- Data from the ongoing Phase 1 Part 3 study is expected in the fourth quarter of 2026.
- Pre-clinical models showed DA-1726 improved weight loss compared to semaglutide (Wegovy®).
- Phase 1 multiple ascending dose trial demonstrated best-in-class potential for weight loss and glucose control.
Price Impact
More from MTVA